SCHEMBL3002344

SCHEMBL3002344

COc1ccc(OC)c(Cc2csc(N3CCN(S(=O)(=O)c4ccccc4C(F)(F)F)CC3)n2)c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.47
L3MBTL1 Q9Y468 2/20 0.47
USP2 O75604 2/20 0.47
LMNA P02545 2/20 0.47
HTT P42858 2/20 0.47
KMT2A Q03164 3/20 0.44
MEN1 O00255 1/20 0.44
KDM4E B2RXH2 1/20 0.44
MAPT P10636 2/20 0.44
RECQL P46063 2/20 0.44
IDO1 P14902 1/20 0.43
TP53 P04637 1/20 0.43
HSD17B10 Q99714 1/20 0.43
ALOX15 P16050 1/20 0.43
TSHR P16473 1/20 0.43
MAPK1 P28482 1/20 0.43
HSD11B1 P28845 1/20 0.41
GBA1 P04062 2/20 0.41
CHRM4 P08173 1/20 0.41
KCNQ1 P51787 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3646570 0.97 ALDH1A1 (0.44) ALDH1A1L3MBTL1USP2LMNAHTT
SCHEMBL3017111 0.93 ALDH1A1 (0.44) ALDH1A1L3MBTL1USP2LMNAHTT
SCHEMBL3013338 0.91 KMT2A (0.48) ALDH1A1L3MBTL1USP2LMNAHTT
SCHEMBL3013779 0.88 ALDH1A1 (0.49) ALDH1A1L3MBTL1USP2LMNAHTT
SCHEMBL3006881 0.87 ALDH1A1 (0.48) ALDH1A1L3MBTL1USP2LMNAHTT
SCHEMBL3012189 0.87 KMT2A (0.48) ALDH1A1USP2LMNAHTTKMT2A
SCHEMBL3006262 0.87 CTSS (0.42) L3MBTL1LMNAKMT2AMEN1MAPT
SCHEMBL3012014 0.87 ALDH1A1 (0.56) ALDH1A1L3MBTL1USP2LMNAHTT
SCHEMBL3021870 0.87 KMT2A (0.46) ALDH1A1L3MBTL1USP2LMNAHTT
SCHEMBL3013853 0.87 MAPT (0.48) ALDH1A1USP2LMNAHTTKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2188272-B1 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES REMYND NV (BE) 2016-02-24 EP disclosed
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA ALDH1A1 3510/4885L3MBTL1 1847/4885USP2 1831/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.